List of Piqray drug patents
Piqray is owned by Novartis.
Piqray contains Alpelisib.
Piqray has a total of 2 drug patents out of which 0 drug patents have expired.
Piqray was authorised for market use on 24 May, 2019.
Piqray is available in tablet;oral dosage forms.
Piqray can be used as in combination with fulvestrant for treatment of postmenopausal women, and men, with hr-positive, her-2-negative, pik3ca-mutated, advanced or metastatic breast cancer.
Drug patent challenges can be filed against Piqray from May, 2023.
The generics of Piqray are possible to be released after 28 September, 2030.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8476268 | NOVARTIS | Pyrrolidine-1,2-dicarboxamide derivatives |
Sep, 2029
(6 years from now) | |
| US8227462 | NOVARTIS | Pyrrolidine-1,2-dicarboxamide derivatives |
Sep, 2030
(7 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | May 24, 2024 |
Drugs and Companies using ALPELISIB ingredient
NCE-1 date: May, 2023
Market Authorisation Date: 24 May, 2019
Treatment: In combination with fulvestrant for treatment of postmenopausal women, and men, with hr-positive, her-2-negative, pik3ca-mutated, advanced or metastatic breast cancer
Dosage: TABLET;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic